TX-PLANVIEW
5.7.2022 15:05:08 CEST | Business Wire | Press release
Planview , a global leader in Portfolio Management and Work Management solutions, today announced it has completed its acquisition of Tasktop, initially announced on May 18 .
“Bringing Mik Kersten and the Tasktop team into Planview will help deliver new levels of excellence to companies and industries navigating through change,” said Razat Gaurav, CEO of Planview. “By merging Tasktop’s institutional expertise in scaling software with Planview’s focus on delivering enterprise-scale visibility, we’ve created a new industry powerhouse poised to help organizations connect the business of software delivery and conduct their business transformations with unprecedented confidence and efficiency.”
The combination of Planview and Tasktop means customers work with a single, comprehensive organization with cutting-edge expertise in capabilities ranging from Value Stream Management (VSM) to Strategic Portfolio Management and Enterprise Agile Planning, among others. At a time when organizations are navigating business transformations amid a turbulent macroeconomic landscape, having a single partner that provides intelligence and visibility into the progress of those transformations helps ensure success.
According to a May 2022 Forrester blog, The Market For VSM And SPM Takes A Big Step Forward , “We see the Planview + Tasktop combination having the potential to shake up the (Strategic Portfolio Management) SPM and VSM marketplace and force it to evolve at an even faster pace by putting pressure on existing leaders in agile planning and DevOps management solutions.”
“To succeed with digital transformation, organizations must expand beyond Agile teams to portfolio-level business agility,” said Dean Leffingwell, creator of SAFe® and cofounder, Scaled Agile, Inc. “We’re headed in the right direction. With so many enterprises now deploying SAFe, and the shift from project to product described in Mik Kersten’s book gaining mind share, this new way of working and thinking is finding its way into the CEO’s office. This new paradigm is helping leaders effectively connect the strategic portfolio level with software delivery, which introduces huge opportunities for the business. It is great to see our Scaled Agile partners Planview and Tasktop coming together to help enterprises maximize and accelerate those opportunities.”
The newly combined entity affirms Planview’s leading position globally with 4,500 enterprise customers worldwide, more than 1,300 employees, and a combined FY21 revenue of approximately $400 million. Planview will continue to invest in and support the Tasktop product lines as standalone solutions in the immediate term and will evaluate product direction long term based on customer and industry feedback. As part of the transaction, Tasktop cofounder and CEO, Mik Kersten, has joined Planview as Chief Technology Officer. You can read more about the Tasktop team’s go-forward focus in Mik’s blog .
Sumeru Equity Partners , Tasktop’s lead investor, along with minority investors Elsewhere Partners and Yaletown Partners, and Tasktop’s management will be rolling part of their equity in the new combined entity and will maintain minority interest in Planview alongside its majority shareholders, TPG and TA Associates. Golub Capital provided committed debt financing and Jefferies LLC acted as financial advisors to Planview. Ropes & Gray served as legal counsel to Planview. AGC Partners acted as financial advisors to Tasktop / Sumeru Equity Partners, and Kirkland & Ellis served as legal counsel.
About Planview
Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions create an organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220704005348/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bregal Milestone Backs Nethive With Majority Growth Investment and JoyComm Acquisition22.10.2026 10:00:00 CEST | Press release
Partnership to support Nethive’s next phase of growth as a leading cybersecurity services and software platform Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in Nethive S.p.A. (“Nethive” or the “Company”), a leading Italian cybersecurity services and software provider. Alongside its investment in Nethive, Bregal Milestone has also backed Nethive’s acquisition of IT security specialist Joy Comm S.r.l. (“JoyComm”). Founded in 2014 by Alessandro Bellato and Diego Rocco, Nethive has become a trusted cybersecurity partner to blue-chip enterprises, SMEs, and public-sector organizations across Italy. Its platform spans managed security services, professional services and technology resale, helping organizations protect critical infrastructure and networks, strengthen cyber resilience and reduce operational complexity. Nethive combines deep technical expertise with 24/7 monitoring, threat detection and response, risk and
EOS and VOP CZ Sign Memorandum of Understanding to Explore Cooperation on Czech Programmes22.10.2026 09:00:00 CEST | Press release
EOS Defence Systems (EOS) and VOP CZ have signed a Memorandum of Understanding (MoU) at Future Forces Forum in Prague to explore cooperation on wheeled armoured vehicle programmes for the Czech Army and other future defence projects in the Czech Republic and Europe where VOP CZ is involved. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021408045/en/ EOS and VOP CZ sign a Memorandum of Understanding at Future Forces Forum in Prague. Left to right: Martin van de Voorde, Sales Director Europe, EOS; Vlastimil Navrátil, Managing Director, VOP CZ; Pavla Ungrová, Sales Director, VOP CZ; Rear Admiral Richard Caton, Australia’s Military Representative to NATO and the EU; Group Captain Michael Schleeman, Australia’s Defence Attaché; and Matej Pupák, Program Lead, VOP CZ. The agreement brings together EOS' expertise in advanced remote weapon systems (RWS) with VOP CZ's established capabilities in military vehicle integration, produ
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease22.10.2026 09:00:00 CEST | Press release
Ferreri and Prilenia Therapeutics B.V.today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow. Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life. “The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to bu
IQM Quantum Computers Announces Conference Call to Report Third Quarter 2026 Financial Results on November 5, 202622.10.2026 08:00:00 CEST | Press release
As published previously, IQM Quantum Computers Plc (Nasdaq: IQMX) ("IQM" or the "Company"), a global leader in superconducting quantum computers, will report financial results for the third quarter 2026 on Thursday, November 5, 2026. CEO Dr. Jan Goetz and CFO Jan Kuerschner will host a conference call at 3:00 PM EET / 2:00 PM CET / 8:00 AM EST on the same day followed by a Q&A session with analysts. Conference Call and Webcast A live audio webcast of the conference call will be available to the public through the link below and can be accessed in the News & Events section of IQM's Investor Relations website at https://investors.iqm.tech/. A replay of the call will be available at the same location for one year following the call. Participation in the Q&A during the conference call will require registration using the link below. Date: Thursday, November 5, 2026 Time: 3:00 PM EET / 2:00 PM CET / 8:00 AM EST Webcast Link: https://edge.media-server.com/mmc/p/syqjnhp6To ask questions on the
Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance22.10.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. Record net sales of 4.765 billion USD for thefirst nine months of 2026, representing 25.1% year-on-year growth at constant currency1, predominantly driven by volume and complemented by favorable mix. Broad-based double-digit growth across geographies and product categories, reflecting strong execution of Galderma’s proven integrated dermatology strategy, with stand-out performance in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators. Continued market outperformance across all three product categories, with net sales growth year-on-year at constant currency of 13.2% in Injectable Aesthetics, 16.2% in Dermatological Skincare, and 64.4% in Therapeutic Dermatology (with Nemluvio net sales of 735 million USD). Strengthening Ga
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
